Resveratrol protects mesangial cells under high glucose by regulating the miR-1231/IGF1/ERK pathway.
ERK signaling pathway
MiR-1231
diabetic nephropathy
mesangial cells
resveratrol
Journal
Environmental toxicology
ISSN: 1522-7278
Titre abrégé: Environ Toxicol
Pays: United States
ID NLM: 100885357
Informations de publication
Date de publication:
29 Dec 2023
29 Dec 2023
Historique:
revised:
13
11
2023
received:
03
10
2023
accepted:
10
12
2023
medline:
29
12
2023
pubmed:
29
12
2023
entrez:
29
12
2023
Statut:
aheadofprint
Résumé
Diabetic nephropathy (DN) is one of the complications of diabetes mellitus and the main cause of end-stage renal disease (ESRD), which is a serious threat to human health. In DN, mesangial cells (MCs) are a critical target cell that perform a variety of key functions, and abnormal proliferation of MCs is a common and prominent pathological change in DN. In recent years, the investigation of Chinese medicine interventions for DN has increased significantly in recent years due to the many potential adverse effects and controversies associated with the treatment of DN with Western medicines. In this study, we evaluated the protective effect of resveratrol (RES), an active ingredient known as a natural antioxidant, on HMCs under high glucose and explored its possible mechanism of action. We found that RES inhibited the proliferation of human mesangial cell (HMC) under high glucose and blocked cell cycle progression. In the high glucose environment, RES upregulated miR-1231, reduced IGF1 expression, inhibited the activity of the extracellular signal-regulated kinase (ERK) signaling pathway and reduced levels of the inflammatory factors TNF-α and IL-6. In addition, we found that miR-1231 mimics were synergistically inhibited with RES, whereas miR-1231 inhibitor attenuated the protective effect of RES on HMCs. Thus, our results suggest that the protective effect of RES on HMCs under high glucose is achieved, at least in part, through modulation of the miR-1231/IGF1/ERK pathway. The discovery of this potential mechanism may provide a new molecular therapeutic target for the prevention and treatment of DN, and may also bring new ideas for the clinical research in DN.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Tibet Autonomous Region Science and Technology Programme
ID : CGZH2023000195
Organisme : Science and Technology Project from the Education Department of Jilin Province
ID : JJKH20221102KJ
Organisme : Jilin Province Science and Technology Department
ID : 20210101378JC
Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Samsu N. Diabetic nephropathy: challenges in pathogenesis, diagnosis, and treatment. Biomed Res Int. 2021;2021:1497449.
Younes-Ibrahim M. Mesangial cells: renal function protagonists or coadjuvants? J Bras Nefrol. 2013;35(4):248-249.
Tung CW, Hsu YC, Shih YH, Chang PJ, Lin CL. Glomerular mesangial cell and podocyte injuries in diabetic nephropathy. Nephrology (Carlton). 2018;23(Suppl 4):32-37.
Chen L, Heikkinen L, Wang C, Yang Y, Sun H, Wong G. Trends in the development of miRNA bioinformatics tools. Brief Bioinform. 2019;20(5):1836-1852.
Saliminejad K, Khorram Khorshid HR, Soleymani Fard S, Ghaffari SH. An overview of microRNAs: biology, functions, therapeutics, and analysis methods. J Cell Physiol. 2019;234(5):5451-5465.
Sengupta D, Deb M, Kar S, et al. Dissecting miRNA facilitated physiology and function in human breast cancer for therapeutic intervention. Semin Cancer Biol. 2021;72:46-64.
Mellis D, Caporali A. MicroRNA-based therapeutics in cardiovascular disease: screening and delivery to the target. Biochem Soc Trans. 2018;46(1):11-21.
Vasu S, Kumano K, Darden CM, Rahman I, Lawrence MC, Naziruddin B. MicroRNA signatures as future biomarkers for diagnosis of diabetes states. Cell. 2019;8(12):1533.
Canaud G, Bonventre JV. Cell cycle arrest and the evolution of chronic kidney disease from acute kidney injury. Nephrol Dial Transplant. 2015;30(4):575-583.
Xu S, Lv Y, Zhao J, Wang J, Wang G, Wang S. The inhibitory effect of Rhein on proliferation of high glucose-induced mesangial cell through cell cycle regulation and induction of cell apoptosis. Pharmacogn Mag. 2016;12(Suppl 2):S257-S263.
Wang Z. Regulation of cell cycle progression by growth factor-induced cell signaling. Cell. 2021;10(12):3327.
Sheng J, Liu K, Sun D, et al. Association of RDM1 with osteosarcoma progression via cell cycle and MEK/ERK signalling pathway regulation. J Cell Mol Med. 2021;25(16):8039-8046.
Tian X, Geng J, Zheng Q, et al. Single high dose irradiation induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cells through the Ras/Raf/MEK/ERK pathways. Int J Radiat Biol. 2020;96(6):740-747.
Tanimura S, Takeda K. ERK signalling as a regulator of cell motility. J Biochem. 2017;162(3):145-154.
Weigert C, Sauer U, Brodbeck K, Pfeiffer A, Häring HU, Schleicher ED. AP-1 proteins mediate hyperglycemia-induced activation of the human TGF-beta1 promoter in mesangial cells. J Am Soc Nephrol. 2000;11(11):2007-2016.
Wang Y, Liu D, Zhao H, et al. Cordyceps sinensis polysaccharide CPS-2 protects human mesangial cells from PDGF-BB-induced proliferation through the PDGF/ERK and TGF-β1/Smad pathways. Mol Cell Endocrinol. 2014;382(2):979-988.
Singh N, Baby D, Rajguru JP, Patil PB, Thakkannavar SS, Pujari VB. Inflammation and cancer. Ann Afr Med. 2019;18(3):121-126.
Tasneem S, Liu B, Li B, Choudhary MI, Wang W. Molecular pharmacology of inflammation: medicinal plants as anti-inflammatory agents. Pharmacol Res. 2019;139:126-140.
Liu E, Lv L, Zhan Y, et al. METTL3/N6-methyladenosine/ miR-21-5p promotes obstructive renal fibrosis by regulating inflammation through SPRY1/ERK/NF-κB pathway activation. J Cell Mol Med. 2021;25(16):7660-7674.
Rayego-Mateos S, Morgado-Pascual JL, Opazo-Ríos L, et al. Pathogenic pathways and therapeutic approaches targeting inflammation in diabetic nephropathy. Int J Mol Sci. 2020;21(11):3798.
Pérez-Morales RE, Del Pino MD, Valdivielso JM, Ortiz A, Mora-Fernández C, Navarro-González JF. Inflammation in diabetic kidney disease. Nephron. 2019;143(1):12-16.
Galiniak S, Aebisher D, Bartusik-Aebisher D. Health benefits of resveratrol administration. Acta Biochim Pol. 2019;66(1):13-21.
Lin AV. Direct ELISA. Methods Mol Biol. 2015;1318:61-67.
Sattar L, Renneboog B, Decaux G. Hyperglycemia induces attention and gait deficits in diabetic mellitus patients. Acta Diabetol. 2017;54(10):953-959.
Tiwari R, Wal P, Singh P, Tiwari G, Rai A. A review on mechanistic and pharmacological findings of diabetic peripheral neuropathy including pharmacotherapy. Curr Diabetes Rev. 2021;17(3):247-258.
Alesci A, Nicosia N, Fumia A, Giorgianni F, Santini A, Cicero N. Resveratrol and immune cells: a link to improve human health. Molecules (Basel, Switzerland). 2022;27(2):424.
Zhang L, Pang S, Deng B, et al. High glucose induces renal mesangial cell proliferation and fibronectin expression through JNK/NF-κB/NADPH oxidase/ROS pathway, which is inhibited by resveratrol. Int J Biochem Cell Biol. 2012;44(4):629-638.
Hoca M, Becer E, Vatansever HS. The role of resveratrol in diabetes and obesity associated with insulin resistance. Arch Physiol Biochem. 2023;129(2):555-561.
Uzbekov R, Prigent C. A journey through time on the discovery of cell cycle regulation. Cell. 2022;11(4):704.
Ni WJ, Guan XM, Zeng J, Zhou H, Meng XM, Tang LQ. Berberine regulates mesangial cell proliferation and cell cycle to attenuate diabetic nephropathy through the PI3K/Akt/AS160/GLUT1 signalling pathway. J Cell Mol Med. 2022;26(4):1144-1155.
Gallo S, Vitacolonna A, Bonzano A, Comoglio P, Crepaldi T. ERK: a key player in the pathophysiology of cardiac hypertrophy. Int J Mol Sci. 2019;20(9):2164.
Zhang GY, Wang DD, Cao Z, Wei T, Liu CX, Wei QL. Sitagliptin ameliorates high glucose-induced cell proliferation and expression of the extracellular matrix in glomerular mesangial cells. Exp Ther Med. 2017;14(4):3862-3867.
Chen C, Shi Y, Ma J, Chen Z, Zhang M, Zhao Y. Trigonelline reverses high glucose-induced proliferation, fibrosis of mesangial cells via modulation of Wnt signaling pathway. Diabetol Metab Syndr. 2022;14(1):28.
Gong W, Li J, Chen W, Feng F, Deng Y. Resveratrol inhibits lipopolysaccharide-induced extracellular matrix accumulation and inflammation in rat glomerular mesangial cells by SphK1/S1P2/NF-κB pathway. Diabetes Metab Syndr Obes. 2020;13:4495-4505.
Hill M, Tran N. miRNA interplay: mechanisms and consequences in cancer. Dis Model Mech. 2021;14(4):dmm047662.
Sun J, Wang J, Lu W, et al. MiR-325-3p inhibits renal inflammation and fibrosis by targeting CCL19 in diabetic nephropathy. Clin Exp Pharmacol Physiol. 2020;47(11):1850-1860.
Wu J, Lu K, Zhu M, et al. miR-485 suppresses inflammation and proliferation of mesangial cells in an in vitro model of diabetic nephropathy by targeting NOX5. Biochem Biophys Res Commun. 2020;521(4):984-990.
Wen X, Jiao L, Tan H. MAPK/ERK pathway as a central regulator in vertebrate organ regeneration. Int J Mol Sci. 2022;23(3):1464.
Disser NP, Sugg KB, Talarek JR, Sarver DC, Rourke BJ, Mendias CL. Insulin-like growth factor 1 signaling in tenocytes is required for adult tendon growth. FASEB J. 2019;33(11):12680-12695.
Hakuno F, Takahashi SI. IGF1 receptor signaling pathways. J Mol Endocrinol. 2018;61(1):T69-T86.
Donegan D, Bale LK, Conover CA. PAPP-A in normal human mesangial cells: effect of inflammation and factors related to diabetic nephropathy. J Endocrinol. 2016;231(1):71-80.
Ren N, Shi S, Zhao N, Zhang L. Dual specificity phosphatase 22 suppresses mesangial cell hyperproliferation, fibrosis, inflammation and the MAPK signaling pathway in diabetic nephropathy. Exp Ther Med. 2022;24(6):744.
Li J, Xu J, Cao Z, Du S, Zhang L. MiR-1231 decrease the risk of cancer-related mortality in patients combined with non-small cell lung cancer and diabetes mellitus. Cancer Cell Int. 2020;20:438.
Su M, Zhao W, Xu S, Weng J. Resveratrol in treating diabetes and its cardiovascular complications: a review of its mechanisms of action. Antioxidants (Basel, Switzerland). 2022;11(6):1085.